Immunovant Reports Q1 FY2026 Results: $153M Net Loss, $798M Cash, Pipeline On Track

summarizeSummary

Immunovant posted a $153.2M net loss for Q1 FY2026, driven by higher R&D for IMVT-1402. Cash of $797.8M provides runway to the potential GD launch, and all six clinical programs remain on schedule.

check_boxKey Events · Earnings and Guidance · IMVT

• Q1 FY2026 Net Loss Widens

  Net loss of $153.2 million ($0.75/share) vs. $120.6 million ($0.71/share) a year ago, driven by a 41% increase in R&D expenses to $142.6 million for IMVT-1402 trials.

• Cash Runway to GD Launch

  Cash and equivalents of $797.8 million as of June 30, 2026, expected to fund operations through the potential commercial launch of IMVT-1402 in Graves' disease.

• Pipeline On Track, Key Data in H2 2026

  All six IMVT-1402 programs remain on schedule; topline data from the potentially registrational D2T RA program and proof-of-concept CLE trial expected in H2 2026.

• R&D Spend Ramping, G&A Declining

  R&D expenses rose to $142.6M from $101.2M, reflecting increased clinical trial and manufacturing costs; G&A fell to $17.7M from $26.0M on lower personnel and professional fees.

auto_awesomeAnalysis · IMVT · Life Sciences

Immunovant's first fiscal quarter results show a widening net loss to $153.2 million as R&D spending ramps for IMVT-1402 across six indications. The $797.8 million cash position is the key number — management says it funds operations through the potential Graves' disease launch, removing near-term financing risk. All clinical timelines are reaffirmed, with two data readouts expected in the second half of 2026. The stock is near its 52-week high, reflecting market optimism around the pipeline, but the rising cash burn rate and recent insider selling warrant attention.